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1. Introduction 
The knowledge of the impact of beta-blockers on Coronary Flow Reserve (CFR) is based on 
experimental and clinical studies which used invasive methods (mainly Doppler Flow Wire, 
DFW) and non-invasive tools including scintigraphic (mainly Positron Emission 
Tomography, PET), magnetic resonance and Doppler ultrasound imaging. 
Beta-blockers have a large therapeutic indication in the treatment of coronary artery disease, 
due to their anti-ischemic and anti-arrhythmic effect. The anti-ischemic effect is based on the 
oxygen sparing mechanism with a reduction in rate-pressure product. Changes in coronary 
hemodynamics associated with the administration of beta-blockers have been extensively 
studied. These drugs may affect CFR by modifying either resting or maximal coronary 
blood flow (CBF) or even both. When assessing the impact of beta-blockers on CFR it is 
important to distinguish the effects exerted by first-and second generation beta-blockers 
from those due the mechanisms of third generation beta-blockers, which are provided of 
vasodilating action.  
2. First and second generation beta-blockers and coronary flow reserve 
Animal and human experiments have shown that first- and second generation beta-blockers 
(propranolol, practolol metoprolol, atenolol) induce a reduction of CBF at rest (1-7), which 
has been mainly attributed to coronary vasoconstriction (8,9). Both non selective 
(propranolol) and selective (atenolol) beta-blocking agents have shown a gradual 
vasoconstriction, i.e., a decrease in coronary artery diameter by approximately 20-25%, over 
20 min after their acute administration, an effect which is overcome by nitrates (3). An 
alternative mechanisms for explaining the reduction of CBF at rest is provided by the 
reduction of myocardial oxygen demand since these drugs lower blood pressure and heart 
rate with variable degree (4,5). After acute injection, beta-blockers decrease myocardial 
contractility and work, leading to a reduction of resting CBF (5).  
The effects of first and second generation beta-blockers on maximal CBF are more 
controversial. A clinical study assessing the effects of non-selective beta-blocker propranolol 
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(0.1 mg/kg i.v.) after cold pressure test (CPT), a stimulus completely mediated to the 
endothelial function (“reactive hyperemia”) suggests that this drug leads to enhanced 
coronary vascular resistance during hyperemia, due to unopposed alpha-adrenergic 
vasomotor tone (6). The oral administration of the cardio-selective atenolol produces similar 
action in hypertensive patients without coronary artery stenosis, inducing even a reduction 
of CFR and raising the suspicion that it may worsen coronary microvascular function (7). On 
the other hand, in patients with coronary artery disease the acute intravenous 
administration of the selective beta-blocker metoprolol (5 mg) has shown an increase of 
pharmacologically induced (adenosine) CBF velocities and post-ischemic coronary flow 
velocity reserve (CFVR) measured by the means of DFW (5). Boettcher and coworker have 
reported similar results, with an increase in PET-derived CFR after 50 mg oral metoprolol, 
achieved by an increase in maximal CBF which is further enhanced by a decrease in resting 
CBF (6).  
Based on these experiences, the controversial influence of first- and second-generation beta-
blocking agents on CFR has to be acknowledged. It can be explained by taking into account 
the interaction of the pharmacological effects on CBF at rest, generally reduced under the 
action of these categories of beta-blockers, and after maximal hyperemia, when minimal 
coronary resistance can be increased (mainly by non selective beta-adrenergic antagonists 
and by selective atenolol) or reduced (by some selective beta-blockers such as metoprolol).      
3. Third generation Beta-blockers (with vasodilating action) and Coronary 
Flow Reserve 
The third generation beta-blockers have the common characteristic to combine a 
vasodilating action to the classic beta-blocking properties. The association of these two 
effects is particularly pronounced in carvedilol and nebivolol, which have earned important 
positions in the therapy of chronic heart failure, with a recognized positive influence on left 
ventricular (LV) function and prognosis (10-13). The influence of these two drugs on CFR 
has been tested in the clinical setting. The improvement of coronary microvascular function 
obtainable by both carvedilol (14-17) and nebivolol (7,18-21) could be at least one of the 
substrates underlying the improvement in LV function due to both these drugs. Except for 
the experience of Koepfli et al (14), where a significant drug-induced  increase on PET-
derived CFR was achieved only pooling 36 patients with coronary artery disease treated by 
either carvedilol or atenolol (12 week treatment), all the other clinical studies demonstrated 
a positive effect of carvedilol or nebivolol on CFR (Table 1) (22).   
The beneficial action of carvedilol on CFVR was observed in three reports, including 
exclusively patients with idiopathic dilated cardiomyopathy, with a therapy time duration 
ranging between 1 month and 6 months (16-18). In these experiences, the increase of CFVR 
was mainly due to the increase of maximal CBF velocity, attributable to diminution of 
extravascular compressive forces and of LV filling pressure (5,6), to blunted heart rate 
response beneficially affecting the diastolic myocardial perfusion during hyperemia (6), to 
alpha-adrenergic blocking action and to improved endothelial function (23,24) possibly 
producing a better hyperemic microvascular vasodilation..  
The studies performed by using nebivolol involved several clinical settings, such as patients 
with arterial hypertension (7,18,21), idiopathic dilated cardiomyopathy (19) and coronary 
artery disease (20). In particular, Togni et al (20) evaluated the acute effect of intracoronary 
administration of nebivolol, while the other studies evaluated the therapeutic effect of oral 
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Drug Authors 
Method for 
measuring CFR 
Setting / 
therapy 
duration 
Effect on CFR 
Carvedilol,        
20 mg/day 
Sugioka K et al,   
JACC 2005 
TTE,               
Aden 0.14 
mg/Kg/min 
12 IDCM pts,  
3-6 months 
2.6±0.9 
(baseline) 
3.5±0.7 
(3 months) 
3.7±0.6 
(6 months) 
Carvedilol 
25-50 mg/day 
Neglia D et al,    
Heart 2007 
PET                
Dip 0.56 mg/Kg 
16 IDCM pts,  
6 months 
1.67±0.63 
(baseline) 
2.58±1.04 
(6 months) 
Carvedilol 
20 mg/day 
Sugioka K et al,   
Am Heart J 2007
TTE, 
Aden 0.14 
mg/Kg/min 
18 IDCM pts,  
1 month 
CFR change = 
1.3±0.6* 
Nebivolol,         
5 mg/day 
Galderisi M et al,  
J Hypertens 2004
TTE, 
Dip 0.56 mg/kg 
14 HTN pts,   
4 weeks 
1.89±0.31 
(baseline) 
2.12±0.33 
(4 weeks) 
Nebivolol,  
5mg/day 
Gullu H et al,     
Heart 2006 
TTE,               
Dip 0.84 mg/Kg 
30 HTN pts,   
8 weeks 
2.45±0.48 
(baseline) 
2.56±0.52 
(8 weeks) 
Nebivolol,         
5 mg/day 
Erdogan D et al, 
Heart 2007 
TTE,               
Dip 0.56 mg/Kg 
21 IDCM pts,  
1 month 
2.02±0.35 
(baseline) 
2.61±0.43 
(1 month) 
Nebivolol,         
0.1 mg, 0.25 mg, 
0.50 mg 
(intracoronary) 
Togni M et al, 
Cardiovasc Drug 
Ther 2007 
DFW,              
Aden 12-18 µg 
(intracoronary) 
8 CAD pts,    
Acute effect 
2.10±0.4 
(baseline) 
2.30±0.7 
(0.1 mg) 
2.60±0.9 
(0.25 mg) 
2.60±0.5 
(0.50 mg) 
Nebivolol         
5 mg/day 
Galderisi M et al,
J Hypertens 2009
TTE, 
Dip 0.84 mg/Kg 
20 HTN pts, 
3 months 
2.07±0.2 
(baseline) 
2.20±0.2 
(3 months) 
* CFR change in patients with improvement of LV ejection fraction ≥ 10%.  
Aden = Adenosine, CAD = Coronary artery disease, DFW = Doppler flow wire, Dip = Dipyridamole, 
HTN = Hypertension IDCM = Idiopathic dilated cardiomyopathy, PET = Positron emission 
tomography, pts = Patients, TTE = Trans-thoracic echocardiography 
Table 1. Main studies showing favourable effect of beta-blockers with vasodilator action on 
CFR in humans (Modified by Galderisi M et al, Ref # 21). 
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administration (5 mg daily) after 8 weeks (7) and 4 weeks (18,19) and 3 months (21). With 
the exception of the observation of Gullu (7), where the improvement of CFVR was 
exclusively due to the decrease of CBF velocities at rest, in the other 4 studies nebivolol 
increased significantly  hyperemic CBF velocities (18-21). Coronary vasodilation due to 
either adenosine or dipyridamole is primarily endothelium independent but the increment 
in CBF may trigger further flow-induced vasodilation, which is endothelium dependent 
(25,26). Nebivolol has vasodilating properties with increasing endothelial NO release due to 
effects on the L-arginine/NO pathway that reduce peripheral vascular resistance (27). It is 
able not only to increase NO release but also to inhibit the synthesis of endothelin-1 (28), a 
mediator contributing to vascular resistance (29). Although these effects cannot be 
automatically applied to the coronary circulation of the studies which demonstrated the 
beneficial effects of nebivolol on CFVR – since they did not use any NO antagonist to target 
the mechanism of action - in our experience (18) dipyridamole-induced increase in rate-
pressure product during pharmacological stress was similar before and during nebivolol 
therapy and could not explain alone the changes induces on CBF velocities. This highlights 
indirectly the possible beneficial effect of the drug on the endothelial function. A similar 
effect of nebivolol has been demonstrated in humans on brachial artery flow mediated 
dilation (30), a completely endothelium-dependent stimulus (31). 
The increase of CFR induced by beta-blocking agents with vasodilating properties has 
potential clinical implications. This increase appears clearly beneficial in patients with 
coronary artery disease, where a better hyperemic CBF (increase of O2 supply), combined 
with a reduction of rate-pressure product (decrease of O2 demand), may be the cause 
underlying the anti-ischemic effect of these drugs. The increase of CFR might also indicate 
an improvement of coronary microvascular dysfunction, responsible of microvascular 
angina pectoris or silent ischemia in patients without epicardial artery stenosis (32). The 
improvement of coronary microvessel function could be even one of the mechanisms 
sustaining the improvement of LV function demonstrated by both carvedilol and nebivolol 
(33-40). Sugioka and coworkers (17) observed that CFVR improvement after carvedilol was 
greater in patients with LV ejection fraction increase ≥ 10% (1.3 ± 0.6) than in those with 
election fraction increase < 10% (0.4 ± 0.5) (p<0.01). Data from our laboratory have shown a 
relation between the positive influence exerted by 3-month oral administration of nebivolol 
on CFVR and the reduction of non invasively determined LV filling pressure in 
uncomplicated arterial hypertension (21). Accordingly, the absence of a significant 
restoration of CFVR after short-term third-generation beta-blockers may imply a poor 
chance of improvement in LV function, while a great CFVR increase may indicate a higher 
chance of it. Therefore, one possible clinical implication is that changes of CFVR after short-
term beta-blocking therapy is helpful to predict the response or the further improvement of 
LV function to treatment.                    
4. Conclusions  
The impact of beta-blocking medications on coronary flow reserve is related to the specific 
characteristics of the drug. First- and second-generation beta-blockers significantly reduce 
coronary flow at rest (because of reduction of myocardial oxygen demand and 
vasoconstriction effects) while their action on the hyperemic coronary flow is variable. 
Third-generation beta-blockers induce a true amelioration of the maximal hyperemia of 
coronary blood flow which appears be possibly due to alpha-adrenergic blockade and to 
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nitric oxide-mediated vasodilator action. These effects might have potential beneficial 
prognostic impact in the setting of patients where CFR reduction has a recognized 
independent, negative predictive value on outcome and mortality (41-43).            
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